Brexit: Scenario Planning Well Under Way At EMA
The EMA has outlined some of the planning that has been going on in preparation for its relocation from the UK to another EU member state as a result of Brexit, including ongoing relations with the UK regulator, the MHRA.
You may also be interested in...
The EMA has given some details of its business continuity plan for Brexit preparedness, which includes diverting some resources from lower-priority tasks to focus on core activities.
European Medicines Agency head Guido Rasi tackles issue of Brexit in agency’s 2016 annual report, saying EMA is “core building block of the common market for medicines in the EU” that operates like “well-oiled machinery.”
The EMA could be landed with a hefty rental bill on top of the actual costs of relocating to another European city, raising questions as to who will bear the financial burden. Meanwhile, the EMA has met with EU regulators to discuss future allocation of work, and Barcelona, Spain’s second city, has officially joined the race to host the agency.